Translational Research Institute solicits game-changing ideas to support astronaut health
Funding topics of current interest are:
- Omics capabilities for use during missions
- Long duration medication stability
- Human brain imaging
- Inflight surgical capabilities
- Increasing organisms’ resistance to radiation
- Pharmaceuticals that preserve muscle mass
- Inflight production of fresh food
- Microbiome based therapies for improving health in spaceflight
- Lymphatic imaging in microgravity
View the details of this TRI research announcement (NNJ16ZSA001N-TRI).
A pre-proposal webinar, during which TRI management will answer questions regarding the research announcement, will be held on March 23, 2017 and is open to all interested proposers. Questions must be submitted in writing at least 24 hours prior to the scheduled webinar to firstname.lastname@example.org. Answers to all questions (FAQ) will be posted on the TRI’s website by March 25, 2017.
Proposers are required to submit a letter of intent through nspires.nasaprs.com by April 10, 2017 in order to submit a full proposal. Full proposals will also be submitted through nspires.nasaprs.com and will be due May 19, 2017.
The Translational Research Institute (TRI) is part of the Center for Space Medicine at Baylor, and is funded by a cooperative agreement from NASA to Baylor College of Medicine with consortium partners California Institute of Technology and Massachusetts Institute of Technology. The Institute’s mission is to lead a national effort in translating cutting-edge, emerging terrestrial research into applied space flight and to support human risk-mitigation for exploration missions beyond low Earth orbit.
Click here to be notified of future TRI solicitation announcements.